ArticleMolecular pharmacology2019
Subcellular Localization and Activity of the Mitogen-Activated Protein Kinase Kinase 7 (MKK7)
Open access · hybridAbstract read
In one paragraph
Article in Molecular pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- JNK Cascade-Induced Apoptosis-A Unique Role in GqPCR Signaling.International journal of molecular sciences · 2023Review
- Review
- Calcineurin in the heart: New horizons for an old friend.Cellular signalling · 2021Review
- Identifying New Substrates and Functions for an Old Enzyme: Calcineurin.Cold Spring Harbor perspectives in biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Emily S GibsonDepartment of Pharmacology (E.S.G., K.M.W., M.L.D.) and Department of Medicine, Division of Renal Diseases and Hypertension (R.A.N.), University of Colorado School of Medicine, Aurora, Colorado; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado (L.E.H.); Immune Disease Institute, Harvard Medical School, Boston, Massachusetts (H.L.); and La Jolla Institute for Allergy and Immunology, La Jolla, California (P.G.H.).
Kevin M WoolfreyDepartment of Pharmacology (E.S.G., K.M.W., M.L.D.) and Department of Medicine, Division of Renal Diseases and Hypertension (R.A.N.), University of Colorado School of Medicine, Aurora, Colorado; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado (L.E.H.); Immune Disease Institute, Harvard Medical School, Boston, Massachusetts (H.L.); and La Jolla Institute for Allergy and Immunology, La Jolla, California (P.G.H.).
Huiming LiDepartment of Pharmacology (E.S.G., K.M.W., M.L.D.) and Department of Medicine, Division of Renal Diseases and Hypertension (R.A.N.), University of Colorado School of Medicine, Aurora, Colorado; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado (L.E.H.); Immune Disease Institute, Harvard Medical School, Boston, Massachusetts (H.L.); and La Jolla Institute for Allergy and Immunology, La Jolla, California (P.G.H.).
Patrick G HoganDepartment of Pharmacology (E.S.G., K.M.W., M.L.D.) and Department of Medicine, Division of Renal Diseases and Hypertension (R.A.N.), University of Colorado School of Medicine, Aurora, Colorado; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado (L.E.H.); Immune Disease Institute, Harvard Medical School, Boston, Massachusetts (H.L.); and La Jolla Institute for Allergy and Immunology, La Jolla, California (P.G.H.).
Raphael A NemenoffDepartment of Pharmacology (E.S.G., K.M.W., M.L.D.) and Department of Medicine, Division of Renal Diseases and Hypertension (R.A.N.), University of Colorado School of Medicine, Aurora, Colorado; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado (L.E.H.); Immune Disease Institute, Harvard Medical School, Boston, Massachusetts (H.L.); and La Jolla Institute for Allergy and Immunology, La Jolla, California (P.G.H.).
Lynn E HeasleyDepartment of Pharmacology (E.S.G., K.M.W., M.L.D.) and Department of Medicine, Division of Renal Diseases and Hypertension (R.A.N.), University of Colorado School of Medicine, Aurora, Colorado; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado (L.E.H.); Immune Disease Institute, Harvard Medical School, Boston, Massachusetts (H.L.); and La Jolla Institute for Allergy and Immunology, La Jolla, California (P.G.H.).
Mark L Dell'AcquaDepartment of Pharmacology (E.S.G., K.M.W., M.L.D.) and Department of Medicine, Division of Renal Diseases and Hypertension (R.A.N.), University of Colorado School of Medicine, Aurora, Colorado; Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado (L.E.H.); Immune Disease Institute, Harvard Medical School, Boston, Massachusetts (H.L.); and La Jolla Institute for Allergy and Immunology, La Jolla, California (P.G.H.) mark.dellacqua@ucdenver.edu.
La Jolla Institute for Immunology · USUniversity of Colorado Denver · USHarvard University · US
Funding
Tissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8MSIGNAL TRANSDUCTION AND GENE INDUCTION IN T LYMPHOCYTESR01AI040127 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HOGAN, PATRICK, RAO, ANJANA · 1996 to 2025
$13.3MNFAT, bZIP proteins, and transcriptional programs in lymphocytesR01AI109842 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Patrick Hogan, Anjana Rao · 2014 to 2026
$8.6MRegulation of Calcium-permeable AMPA Receptors by AKAP79 Postsynaptic SignalingR01NS040701 · NINDS · UNIVERSITY OF COLORADO DENVER · PI DELL'ACQUA, MARK L · 2001 to 2023
$7.7MMechanisms of Neuronal Calcineurin-NFAT Synapse-to-Nucleus SignalingR01MH102338 · NIMH · UNIVERSITY OF COLORADO DENVER · PI DELL'ACQUA, MARK L · 2014 to 2019
$2.2MEicosanoids in Lung Cancer: Progression and MetastasisR01CA162226 · NCI · UNIVERSITY OF COLORADO DENVER · PI NEMENOFF, RAPHAEL A. · 2013 to 2017
$1.6MRole of JNK Pathway in Lung TumorigenesisR01CA116527 · NCI · UNIVERSITY OF COLORADO DENVER · PI HEASLEY, LYNN E · 2007 to 2011
$1.3MRegulation of AKAP79 Postsynaptic Targeting and SignalingR56NS040701 · NINDS · UNIVERSITY OF COLORADO DENVER · PI DELL'ACQUA, MARK L · 2013 to 2013
$540kBioinformatic strategy to identify calcineurin interactors in the human proteomeR03AI090428 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI LI, HUIMING · 2010 to 2011
$196kNCI NIH HHS P50 CA058187NCI NIH HHS R01 CA116527NCI NIH HHS R01 CA162226NIAID NIH HHS R01 AI040127NIAID NIH HHS R01 AI109842NIAID NIH HHS R03 AI090428NIMH NIH HHS R01 MH102338NINDS NIH HHS R01 NS040701NINDS NIH HHS R56 NS040701
Abstract
Calcineurin (CaN) phosphatase signaling is regulated by targeting CaN to substrates, inhibitors, and scaffold proteins containing docking motifs with the consensus sequence of PxIxIT. Here, we identify the docking of CaN to the
Indexed as
Alternative SplicingAmino Acid SequenceAnimalsBinding SitesCell LineCell NucleusChlorocebus aethiopsCOS CellsCytoplasmHEK293 CellsHumansJNK Mitogen-Activated Protein KinasesMAP Kinase Kinase 7Muscle, Smooth, VascularMyocytes, Smooth MusclePhosphoric Monoester Hydrolasescalcineurin phosphataseJNK Mitogen-Activated Protein KinasesMAP Kinase Kinase 7Phosphoric Monoester HydrolasesProtein Isoforms
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.